Opportunities for Investigators

  1. Our Science

Contents

New discoveries and advancements in patient care rely on the sharing of scientific knowledge and expertise. UCB actively collaborates with a strong global network of internationally renowned scientists, academic institutions, and other leading pharmaceutical companies to support the discovery and evaluation of new treatments.

Clinical Trial Data Sharing

Through multiple clinical trials in a variety of disease areas, UCB has generated a wealth of data in patients living with immunologic conditions. UCB is committed to sharing information about our clinical trials and making the results of these studies publically available. By making patient-level data from UCB clinical studies available to our scientific collaborators, we help support analyses that will inform and guide patient care.

Qualified researchers may request access to anonymized patient-level data and supporting documents that have been redacted to protect personally identifiable information from UCB-sponsored clinical studies via ClinicalStudyDataRequest.com (CSDR). CDSR is a consortium of clinical study Sponsors/Funders that facilitates the responsible sharing of patient-level data from a range of clinical study Sponsors/ Funders through a research-friendly platform.

In addition to the studies already listed on CDSR, UCB will consider ad hoc requests for additional Phase II-IV UCB-sponsored interventional clinical studies that started on or after January 1, 2007 to be added to CDSR.

Should you have any questions, you can contact us at datasharing@ucb.com

Submit Data Request

Investigator-Initiated Studies

Through our Investigator-Initiated Studies program, UCB supports unsolicited and independently initiated and conducted studies that contribute to the understanding of immunologic conditions and drive advancements in patient care. 

Therapeutic Areas of Interest in Immunology

UCB is primarily focused on the following areas of therapeutic expertise: 

  • Ankylosing Spondylitis 
  • Axial Spondyloarthritis 
  • Crohn’s Disease*
  • Psoriasis 
  • Psoriatic Arthritis 
  • Rheumatoid Arthritis 
  • Systemic Lupus Erythematosus

As part of this program, UCB accepts unsolicited requests for funding and/or investigational drug supplies to support these studies. Should you have any questions, you may contact your local UCB Medical Science Liaison.

*Requests for the therapeutic area of Gastroenterology (Crohn's Disease) should be submitted to Ferring Pharamceuticals via the following link: https://ferring.envisionpharma.com/vt_ferring/

For information on therapeutic areas of interest outside of Immunology, please visit https://www.ucb.com/our-company/funding/usa

Submitting a Concept:

To submit a concept, please click the link below to access the eRequest Online Submission Portal. 

Submit an IIS Concept

All concepts submitted will be evaluated by a Review Committee. If a concept is recommended for a full proposal submission, an IIS Team member will contact the applicant with further instructions. 

For inquiries regarding the IIS process, please email IISmailbox@ucb.com

UCB Clinical Trial Investigator

If you are interested in being an investigator for a UCB-sponsored clinical trial, please forward your curriculum vitae, including a brief description of your therapeutic area specialty, along with the NCT number of the study you are interested in (if applicable) to:

ucbcares@ucb.com

fax: 740-970-8859

UCB Pharmaceuticals
1950 Lake Park Drive,
Smyrna, GA 30080